SLCO1B1 and prostate carcinoma: This is the first study indicating that SLCO1B1, SLCO1B1, and SLCO2B1 is significantly expressed (or expression is reduced) in a variety to tumors, including: colon cancer, liver cancer, pancreatic cancer, prostate cancer, testicular cancer, and thyroid cancer.